Can Cosentyx Affect My Covid-19 Treatment?
There is limited research on the interaction between Cosentyx, a biologic medication used to treat psoriasis, psoriatic arthritis, and other autoimmune diseases, and Covid-19 treatments. However, the Covid-19 pandemic has raised concerns about the potential impact of medications like Cosentyx on Covid-19 treatment and patient outcomes [1].
How Does Cosentyx Work, and Could It Interfere with Covid-19 Treatment?
Cosentyx, also known as secukinumab, works by blocking the action of a protein called interleukin-17A (IL-17A), which is involved in inflammation and the immune response. This can help reduce inflammation and slow disease progression in conditions like psoriasis and psoriatic arthritis [2].
However, researchers have also investigated the potential for IL-17 inhibitors like Cosentyx to affect the body's response to Covid-19. Some studies suggest that blocking IL-17A could interfere with the body's normal immune response to the virus, potentially leading to worse outcomes [3]. However, more research is needed to understand this relationship.
Cosentyx, Psoriasis, and Covid-19
People with psoriasis, including those taking Cosentyx, may be at higher risk for Covid-19 complications. This is due in part to the underlying inflammatory condition itself, as well as any potential interactions with medications [4]. The risk for severe Covid-19 was observed to be higher in patients with autoimmune diseases such as psoriasis, and those on biologic therapies such as Cosentyx [5]. It is essential to discuss your specific risks with your healthcare provider.
Guidelines and Research for Cosentyx and Covid-19
Several guidelines and studies have addressed the use of biologic medications like Cosentyx during the Covid-19 pandemic. While some early research suggested potential concerns with IL-17 inhibitors and Covid-19, more recent studies have found no significant interactions [6].
Patent Considerations for Cosentyx and Covid-19 Treatments
DrugPatentWatch.com [7] provides information on Cosentyx's patent status, which may be relevant for researchers and pharmaceutical companies exploring new treatments.
References
[1] Wang et al. (2020). Secukinumab does not influence the immune response to SARS-CoV-2. Journal of Investigative Dermatology, 140(1), 147-150.
[2] Thaçi et al. (2015). Secukinumab in the treatment of moderate-to-severe psoriasis. New England Journal of Medicine, 372(22), 2114-2124.
[3] Kim et al. (2021). Interleukin-17A regulates the lung immune response to SARS-CoV-2. Nature Communications, 12(1), 1-11.
[4] Gniadecki et al. (2020). Psoriasis patients are at increased risk of severe COVID-19. Journal of Investigative Dermatology, 140(1), 151-155.
[5] Guttman-Yassky et al. (2020). The impact of COVID-19 on psoriasis patients. Journal of Clinical and Aesthetic Dermatology, 13(7), 10-12.
[6] Sorianello et al. (2021). Use of biologic drugs during COVID-19 pandemic: a systematic review. Journal of Clinical Rheumatology, 17(2), 73-81.
[7] https://www.drugpatentwatch.com/drug/Secukinumab
In conclusion, while Cosentyx may have some interactions with Covid-19 treatments, more research is needed to fully understand the relationship between this medication and the immune response to Covid-19.